Pharmacologic considerations in the treatment of substance abuse.
Drug and alcohol abuse continue to be commonly encountered problems in most patient populations. To deal effectively with these problems, the primary care physician must have a thorough knowledge of the pharmacology of commonly abused drugs and the adjunctive agents used in treatment. Management of alcoholism may involve a range of medical interventions, including the treatment of alcohol intoxication, the use of benzodiazepines for alcohol withdrawal, and possibly the short-term administration of disulfiram to maintain sobriety. Successful management of cocaine or amphetamine abuse requires an understanding of the powerful reinforcing properties of these drugs and the unique problems that arise in the recovery period. Barbiturate intoxication and withdrawal are potentially life-threatening events requiring skilled in-patient treatment. Prolonged use of benzodiazepines can lead to drug dependence; successful withdrawal involves gradual dosage reduction. Acute intoxication from marijuana or hallucinogenic drugs may occasionally result in adverse reactions requiring medical intervention, but significant withdrawal reactions are rare. Management of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid antagonists. Promising new pharmacologic approaches are now being successfully applied to the management of opioid dependence. An acceptance of nicotine as the addictive component of tobacco smoke has led to the development of nicotine gum as substitution therapy for cigarette smoking. Successful pharmacologic management of overdose or withdrawal is often the prerequisite for effective long-term treatment and recovery.
Skinner
M H
MH
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-6205.
Thompson
D A
DA
D000437:Alcoholism / Q000188:drug therapy; D000662:Amphetamines; D003042:Cocaine; D006801:Humans; D006993:Hypnotics and Sedatives; D008238:Lysergic Acid Diethylamide; D009294:Narcotics; D012907:Smoking / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy*
D000662:Amphetamines; D006993:Hypnotics and Sedatives; D009294:Narcotics; D008238:Lysergic Acid Diethylamide; D003042:Cocaine